



Enhanced Annual Drug List Updates

April 2022

TRADE NAME (generic name)	Brand/Generic Product	Description of Change
BIKTARVY (bictegravir-emtricitabine-tenofovir af tab 30-120-15 mg)	Brand	Addition, Preferred Status
DIFICID (fidaxomicin for susp 40 mg/ml)	Brand	Addition, Preferred Status
DIFICID (fidaxomicin tab 200 mg)	Brand	Addition, Preferred Status
DOPTLET (avatrombopag maleate tab 20 mg (base equiv))	Brand	Addition, Preferred Status
DUPIXENT (dupilumab subcutaneous soln prefilled syringe 100 mg/0.67ml)	Brand	Addition, Preferred Status
MYFEMBREE (relugolix-estradiol-norethindrone acetate tab 40-1-0.5 mg)	Brand	Addition, Preferred Status

A division of Health Care Service Corporation, a Mutual Legal Reserve Company, an independent Licensee of the Blue Cross Blue Shield Association. Blue Cross and Blue Shield of Illinois (BCBSIL) contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics LLC.